All In Biotech

Free tool

FAERS Monitor: Primaxin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050587 or its brand name (Primaxin, Cilastatin Sodium, Imipenem). Reports on generic versions are filed under their own applications.

Reports

2,371

Serious

1,943

82% of reports

Hospitalization

1,063

Death reported

560

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication221
  • convulsion188
  • drug ineffective127
  • pyrexia122
  • pneumonia116
  • off label use115
  • sepsis103
  • death91
  • renal failure74
  • septic shock74
  • multi-organ failure72
  • rash72
  • thrombocytopenia72
  • nausea60
  • respiratory failure59

Reports by year received

View as table
YearReports
2004193
2005202
2006175
2007172
2008180
2009211
2010152
2011155
2012163
201325
201427
201519
201629
201744
201865
201981
202056
202185
202267
202399
2024113
202538
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,788 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multi-organ failureSignal7237.129.52,483
convulsionSignal18829.325.55,100
septic shockSignal7415.112.1962
sepsisSignal1038.26.8647
product use in unapproved indicationSignal2217.97.01,343
respiratory failureSignal597.25.6309
thrombocytopeniaSignal725.74.6277
renal failureSignal744.94.0230
pneumoniaSignal1163.22.7174
pyrexiaSignal1223.12.6177
rash721.51.210
off label use1151.21.03
death910.90.80
drug ineffective1270.90.73
nausea600.70.510

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.